ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 140 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.08 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,085,990 | -53.5% | 224,300 | -50.5% | 0.03% | -52.9% |
| Q1 2024 | $4,488,239 | +894.4% | 452,900 | +432.8% | 0.07% | +871.4% |
| Q3 2023 | $451,350 | -78.5% | 85,000 | -61.4% | 0.01% | -81.1% |
| Q2 2023 | $2,096,600 | +172.3% | 220,000 | +214.3% | 0.04% | +146.7% |
| Q1 2023 | $770,000 | -81.1% | 70,000 | -74.6% | 0.02% | -76.6% |
| Q4 2022 | $4,084,800 | +228.9% | 276,000 | +324.6% | 0.06% | +276.5% |
| Q3 2022 | $1,242,000 | +4.2% | 65,000 | +16.3% | 0.02% | 0.0% |
| Q2 2022 | $1,192,000 | +210.4% | 55,910 | +202.2% | 0.02% | +325.0% |
| Q4 2021 | $384,000 | – | 18,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $305,003,000 | 24.46% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $115,121,000 | 6.52% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $16,462,000 | 5.28% |
| SECTORAL ASSET MANAGEMENT INC | 878,948 | $25,428,000 | 1.93% |
| Omega Fund Management, LLC | 623,836 | $18,048,000 | 1.71% |
| Orbimed Advisors | 6,073,850 | $175,716,000 | 1.64% |
| Altium Capital Management LP | 113,962 | $3,297,000 | 0.92% |
| Vivo Capital, LLC | 744,370 | $21,535,000 | 0.76% |
| Polar Capital Holdings Plc | 1,557,543 | $45,060,000 | 0.28% |
| Birchview Capital, LP | 9,000 | $260,000 | 0.15% |